


Targeting the lower regions of the lung: a novel platform for pulmonary mRNA delivery

Rachel Sun

PharmD/ PhD student
Rutgers University

Barriers to lung-targeted therapies

- Primarily target the upper airways of the lung
- Limited targeted delivery to the lower regions of the respiratory system



Ionizable amphiphilic Janus dendrimers (IAJDs)

Delivered mRNAs can be used to increase the expression of protein therapeutics

- Examples include cytokines, peptide hormones, and antioxidant enzymes

Key to therapeutic delivery is:

- Tissue specificity
- Time frame
- Functional processing

IAJDs: one-component Ionizable Amphiphilic Janus Dendrimers

- Single component lipid
- Self assembling

One-Component Ionizable amphiphilic Janus dendrimers (IAJDs)




Image adapted from: <https://doi.org/10.3390/pharmaceutics15061572>


IAJD34 was selected for further characterization

Characteristics of one-component IAJD34

Luc mRNA-IAJD34

Size, nm	97.0 ± 2.4
PDI	0.250 ± 0.01
Encapsulation, %	98.9 ± 0.2
Zeta potential, mV	48.8 ± 4.3

Cryo-TEM of IAJD 34





10 μ g/mouse, 4 hrs post-injection

Whole Body
Radiant Flux (p/s):


4.07×10^7

3.72×10^7

4.28×10^7






Specific and targeted lung delivery over time




Dose-dependent mRNA delivery

24-hours post-injection



No toxicity or signs of inflammation have been observed

Targeted lung parenchyma delivery confirmed by IHC



Summary

- IAJD34 formulated with mRNA specifically targets the lower regions of the lung
- IAJD34 is a potential platform for the treatment of pulmonary injury and disease


Acknowledgements

Drew Weissman Lab:

Drew Weissman
Elena Atochina-Vasserman
Jaclynn Meshanni
Nathan Ona
Wook-Jin Park
Sydni Berkihsier



leap^w R3



Andrew Gow Lab:

Andrew Gow
Changjiang Guo
Elena Abramova



rs1893@pharmacy.rutgers.edu